Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Vincent Lewis

Physician Assistant, Medical Salisbury, MD Physician Assistant

NPI 1275791147 CMS profile 10994621

1324 Belmont Ave Ste 103, Salisbury, MD 21804

Open in the dashboard

General payments

$7,777

458 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Vincent Lewis of Salisbury, MD is reported in the CMS Open Payments database as having received $7,777 across 458 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,317 74
2024 General $1,481 81
2023 General $1,488 88
2022 General $1,860 110
2021 General $1,631 105

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vincent Lewis
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Vincent Lewis were reported at $1,317. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Vincent Lewis Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,631 $156 $41–$563 $132
2022 $1,860 $185 $55–$649 $149
2023 $1,488 $199 $58–$717 $160
2024 $1,481 $206 $62–$740 $164
2025 $1,317 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Lilly USA, LLC $967 54 payments
  2. Pfizer Inc. $593 41 payments
  3. AbbVie, Inc. $535 33 payments
  4. AstraZeneca Pharmaceuticals LP $533 26 payments
  5. GlaxoSmithKline, LLC. $485 33 payments
  6. Novartis Pharmaceuticals Corporation $472 24 payments
  7. Novo Nordisk Inc $470 29 payments
  8. Amgen Inc. $460 27 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $381 26 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $234 14 payments
  11. Other $2,646 151 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,646 453 payments
  2. Education $131 5 payments
Products named General payments · program years 2021–2025
  1. JARDIANCE $497 28 payments
  2. TRELEGY ELLIPTA $485 33 payments
  3. BREZTRI $441 21 payments
  4. NURTEC ODT $432 32 payments
  5. MOUNJARO $427 23 payments
  6. Otezla $373 21 payments
  7. Ozempic $361 23 payments
  8. RYBELSUS $361 23 payments
  9. Repatha $341 19 payments
  10. LEQVIO $270 12 payments
  11. Other $6,881 417 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 140 drugs

Part D claims

8,373

Median for Physician Assistant: 241

Drug cost

$1,039,028

Median for Physician Assistant: $4,110

Branded share of claims

24.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 165 $150,548
Ozempic Semaglutide Brand 78 $86,008
Trulicity Dulaglutide Brand 64 $85,509
Mounjaro Tirzepatide Brand 65 $74,207
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 98 $72,465
Eliquis Apixaban Brand 68 $60,662
Januvia Sitagliptin Phosphate Brand 54 $55,985
Farxiga Dapagliflozin Propanediol Brand 60 $55,621
Tradjenta Linagliptin Brand 33 $37,738
Entresto Sacubitril/Valsartan Brand 31 $36,932

The 10 drugs with the highest cost, of 140 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$121,734

Medicare's payments for the services billed

Medicare patients

361

Average age 70

Services billed

2,158

185 women, 176 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 41%
Chronic kidney disease 38%
Diabetes 35%
Ischemic heart disease 29%
Depression 22%
COPD 16%
Cancer 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $111
$111 — —
NURTEC ODT
  • PFIZER INC. $100
$100 — —
JARDIANCE
  • Lilly USA, LLC $70
  • Boehringer Ingelheim Pharmaceuticals, Inc. $19
$89 165 —
MOUNJARO
  • Lilly USA, LLC $85
$85 65 —
Auvelity
  • Axsome Therapeutics, Inc. $83
$83 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

458 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record